OrbiMed Advisors VRTX Position
Exited4-Fund ConvergenceOrbiMed Advisors exited their position in Vertex Pharmaceuticals Inc. (VRTX) in Q3 2025, after holding the stock for 11 quarters.
The position was first reported in Q1 2023 and has been tracked across 11 quarterly 13F filings.
VRTX is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for VX-993 in 14 days (Apr 30, 2026), making the timing of OrbiMed's position particularly relevant.
About Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Full company profile →Short Interest
1.8%
2.9 days to cover
OrbiMed Advisors VRTX Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q3 2025 | Exited | 0 | -210,287 | $0 |
| Q2 2025 | Increased | 210,287 | +50,387 | $93.6M |
| Q1 2025 | Increased | 159,900 | +8,900 | $77.5M |
| Q4 2024 | Held | 151,000 | — | $60.8M |
| Q3 2024 | Held | 151,000 | — | $70.2M |
| Q2 2024 | Increased | 151,000 | +28,300 | $70.8M |
| Q1 2024 | Decreased | 122,700 | -52,500 | $51.3M |
| Q4 2023 | Increased | 175,200 | +9,800 | $71.3M |
| Q3 2023 | Held | 165,400 | — | $57.5M |
| Q2 2023 | Decreased | 165,400 | -12,200 | $58.2M |
| Q1 2023 | New | 177,600 | +177,600 | $56.0M |
Frequently Asked Questions
Does OrbiMed Advisors own VRTX?
No. OrbiMed Advisors exited their position in Vertex Pharmaceuticals Inc. (VRTX) in Q3 2025. They previously held the stock for 11 quarters.
How many hedge funds own VRTX?
4 specialist biotech hedge funds currently hold VRTX, including Driehaus Capital, Tang Capital Management, Deerfield Management and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy VRTX?
OrbiMed Advisors's position in VRTX was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's VRTX position increasing or decreasing?
OrbiMed Advisors completely exited their VRTX position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
VRTXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →